Nugen Medical Devices Inc · TSXV:NGMD
Nugen Medical Devices — Investor Presentation (October 2021)
16 slides from Nugen Medical Devices's investor presentation, October 2021
Slide 1: Revolutionizing Needle-Free Drug Delivery
TSX.V: NGMD REVOLUTIONIZING Needle-Free DRUG DELIVERY
Slide 2: Our Vision
TSX.V: NGMD Our Vision NuGen Medical Devices believes that every individual should have the opportunity to receive healthcare that is empowering, safe and respectful. 01
Slide 3: Disclaimer
DISCLAIMER TSX.V: NGMD 01 GENERAL The information provided in this presentation pertaining to NuGen Medical Devices ("NuGen MD" or "The Company"), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer t
Slide 4: Global Market Opportunity
GLOBAL MARKET OPPORTUNITY TSX.V: NGMD Injections are a common healthcare procedure, administered to billions every day— but the technique is increasingly going needle-free. GLOBAL VACCINATION GLOBAL NEEDLE-FREE COVERAGE¹ INJECTION SYSTEM MARKET² Current and planned All market values in USD. $25.0B C
Slide 5: Why Needle-Free?
WHY NEEDLE-FREE? TSX.V: NGMD BENEFITS OF NEEDLE-FREE 03 Needle-free REDUCE COSTS delivery is much 05 Patients REDUCE FEAR report less pain and cheaper than the use of needles. discomfort with needle-free Cost Per Million Injections injections, making them more Source: GEN likely to adhere to medicat
Slide 6: That's Where We Come In
THAT’S WHERE WE COME IN. TSX.V: NGMD HOW IT WORKS High-pressure jet injections Traditional needle syringes The company dispense micro-droplets of penetrate the skin, causing medication evenly into the skin. medication to pool over time. has perfected its needle-free devices, NEEDLE-FREE NEEDLE which
Slide 7: Timeline
TIMELINE TSX.V: NGMD Letter of intent Definitive agreement Resulting issuer Received Health Received OSC to acquire EPG with Capital Pool branding Canada Approval Approval of the maker of Insujet™ Company on the TSX Prospectus Venture BuzBuz Capital Filing and TSX-V Listing Approval 2017 2020 2021 2
Slide 8: Key Target Markets
KEY TARGET MARKETS TSX.V: NGMD NuGen MD’s devices can be applied across diverse markets, from home healthcare to diabetes. IVF Services Market Human Growth Hormone Market Global Diabetes Drug Market Adults with Diabetes CAGR (2019-2026): 9.3% CAGR (2020-2027): 8.2% CAGR (2019-2026): 4.3% 2018 $12.5B
Slide 9: Global Reach
GLOBAL REACH TSX.V: NGMD GLOBAL OFFICES In progress: U.S., China EUROPE AMSTERDAM TORONTO FILING Q4 2020 SAUDI ARABIA Available to sell in over 40 countries. SHENZHEN TAIWAN HONG KONG Recently approved by Health Canada in 2021. MALAYSIA BRAZIL AUSTRALIA NEW ZEALAND 08
Slide 10: Nanoparticle Powder Injectable
NANOPARTICLE POWDER INJECTABLE TSX.V: NGMD DISRUPTIVE NEXT-GENERATION DEVICE In emerging countries, camels deliver vaccines in refrigerated and solar-powered containers. THERMOSTABLE IMPROVED EFFICACY CONTROLLED RELEASE New powder drug Demonstrated possible Encapsulation offers the In contrast, nano
Slide 11: Nanojex - Powder Vaccine Injector
NANOJEX - POWDER VACCINE INJECTOR TSX.V: NGMD DEVELOPED, OWNED AND MANUFACTURED IN CANADA BY TRANSDERMAL, POWDER DRUG INJECTION TECHNOLOGY The patented “Nanojex System” painlessly delivers medicines through the skin, using a gas jet to accelerate powdered nanoparticles of drug or protein to superson
Slide 12: Industry Competitors
INDUSTRY COMPETITORS TSX.V: NGMD Current Valuation Comparisons PORTAL NUGEN MD CROSSJECT PHARMAJET INSTRUMENTS HQ: Toronto, Canada HQ: France HQ: Denver, U.S. HQ: Boston, U.S. (In development at MIT) Upsized Funding Round Annual Revenue Annual Revenue CAD$6.0M €2.1M/CAD$3.26M (H1' 2020) US$12M Previ
Slide 13: Notable Advisors
NOTABLE ADVISORS TSX.V: NGMD JOSEPH McCLENDON III VICENTE FOX DR. CAMILLO RICORDI DR. RONALD DENIS Author, Public speaker Former president of Mexico, Director, Diabetes Chief of Surgery and founder of the NGO Research Institute Sacré-Coeur Centro Fox University of Miami Hospital Montreal DR. RICHARD
Slide 14: Board of Directors & Management Team
BOARD OF DIRECTORS & MANAGEMENT TEAM TSX.V: NGMD MICHAEL G. WRIGHT VERONIQUE LABERGE NICKY CANTON CHRIS BROWN CEO, President Chief Financial Officer Chief Operating Officer (COO), Global Capital Markets and Director and Corporate Secretary Design Engineer and MBA DR. JOHN LEOMBRUNO MICHAEL WEKERLE W
Slide 15: Corporate Structure
CORPORATE STRUCTURE TSX.V: NGMD Total Shares Total Escrowed Post-Financing 86.0M Shares 29.6M Total Shares Insider Fully Diluted 106.6M Ownership 20.8% 14
Slide 16: NuGen Medical Devices closing statement
NuGen Medical Devices are a catalyst to the commercialization of innovative needle-free solutions for the cure and care of the global community.
NuGen Medical Devices — Investor Presentation (October 2021) on 6ix